Biogen Inc
BIIB
查看詳細走勢圖
187.620USD
+1.620+0.87%
收盤 01/09, 16:00（美東）報價延遲15分鐘
27.52B總市值
17.07本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+0.87%
5天
+5.51%
1月
+5.67%
6月
+38.64%
今年開始到現在
+6.61%
1年
+26.07%
查看詳細走勢圖
TradingKey Biogen Inc股票評分
單位: USD 更新時間: 2026-01-09操作建議
Biogen Inc當前公司基本面數據相對健康，增長潛力很大。當前估值合理，在藥品行業排名7/159位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為181.86。中期看，股價處於上升通道。近一個月，市場表現較強，技術面和基本面綜合得分較高，較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Biogen Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看空
Biogen Inc亮點
亮點風險
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
分析師目標
基於
36
分析師
買入
評級
181.857
目標均價
+4.14%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Biogen Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Biogen Inc簡介
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
公司代碼BIIB
公司Biogen Inc
CEOViehbacher (Christopher A)
網址https://www.biogen.com/
常見問題
Biogen Inc(BIIB)的當前股價是多少？
Biogen Inc(BIIB)的當前股價是 187.620。
Biogen Inc 的股票代碼是什麼？
Biogen Inc的股票代碼是BIIB。
Biogen Inc股票的52週最高點是多少？
Biogen Inc股票的52週最高點是190.200。
Biogen Inc股票的52週最低點是多少？
Biogen Inc股票的52週最低點是110.035。
Biogen Inc的市值是多少？
Biogen Inc的市值是27.52B。
Biogen Inc的淨利潤是多少？
Biogen Inc的淨利潤為1.63B。
現在Biogen Inc(BIIB)的股票是買入、持有還是賣出？
根據分析師評級，Biogen Inc(BIIB)的總體評級為買入，目標價格為181.857。
Biogen Inc(BIIB)股票的每股收益（EPS TTM）是多少
Biogen Inc(BIIB)股票的每股收益（EPS TTM）是10.991。
相關品種
-1.99%
-0.66%
-1.74%
+0.68%
-0.43%
+0.06%
+2.56%
-1.21%
+0.36%
+0.75%
+1.87%
-1.24%
-0.07%
+0.34%
+0.18%
-1.29%
-0.56%
0.00%
+0.25%
-0.28%
